Q3 2025 Earnings Call Transcript November 6, 2025 AstraZeneca PLC beats earnings expectations. Reported EPS is $1.19, ...

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

The highlight of AstraZeneca's latest results is the maintained full-year outlook despite the recent US drug pricing agreement. Click to read why AZN is a Hold.

AstraZeneca's Q3 sales rose 12% to $15.19 billion, beating forecasts as cancer and biopharma growth lifted results; 2025 ...

British pharmaceutical giant AstraZeneca announced surging quarterly profit Thursday on strong sales of cancer drugs and as ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

The pharma giant disclosed in an earnings report that it paid $170 million up front to acquire SixPeaks Bio, a weight loss-focused startup it helped launch last year.

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

(Reuters) -Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered ...

Popular GLP-1 drugs like Ozempic will get cheaper in exchange for partial Medicare coverage, opening up new markets for Eli ...